CO2017007383A2 - Métodos para utilizar oligonucleótidos antisentido para smad7 - Google Patents

Métodos para utilizar oligonucleótidos antisentido para smad7

Info

Publication number
CO2017007383A2
CO2017007383A2 CONC2017/0007383A CO2017007383A CO2017007383A2 CO 2017007383 A2 CO2017007383 A2 CO 2017007383A2 CO 2017007383 A CO2017007383 A CO 2017007383A CO 2017007383 A2 CO2017007383 A2 CO 2017007383A2
Authority
CO
Colombia
Prior art keywords
smad7
ibd
patient
methods
antisense oligonucleotides
Prior art date
Application number
CONC2017/0007383A
Other languages
English (en)
Inventor
Scott Andrew Smith
Xiaobin Li
Guillermo Rossiter
Philippe L Martin
Seth R Dewacker
Keith Usiskin
Gary Allan Cline
Original Assignee
Celgene Alpine Invest Company Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Alpine Invest Company Ii Llc filed Critical Celgene Alpine Invest Company Ii Llc
Publication of CO2017007383A2 publication Critical patent/CO2017007383A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen métodos para tratar la enfermedad intestinal inflamatoria (IBD) en un paciente que tiene IBD utilizando oligonucleótidos antisentido para SMAD7. En un aspecto, se proporciona en la presente un método para tratar o manejar la enfermedad intestinal inflamatoria (IBD) en un paciente que tiene IBD, en donde el método comprende (a) administrar al paciente un oligonucleótido antisentido para SMAD7 (AON para SMAD7) durante un primer periodo de tratamiento en una primera dosis; y (b) administrar al paciente el oligonucleótido antisentido para SMAD7 durante un segundo periodo de tratamiento en una segunda dosis. Esta invención es útil en el campo médico del tratamiento de enfermedades intestinales inflamatorias”.
CONC2017/0007383A 2014-12-26 2017-07-25 Métodos para utilizar oligonucleótidos antisentido para smad7 CO2017007383A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462097012P 2014-12-26 2014-12-26
US201562235269P 2015-09-30 2015-09-30
PCT/US2015/000269 WO2016105516A1 (en) 2014-12-26 2015-12-23 Methods of using smad7 antisense oligonucleotides

Publications (1)

Publication Number Publication Date
CO2017007383A2 true CO2017007383A2 (es) 2018-01-05

Family

ID=56151259

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0007383A CO2017007383A2 (es) 2014-12-26 2017-07-25 Métodos para utilizar oligonucleótidos antisentido para smad7

Country Status (17)

Country Link
US (1) US20190112608A1 (es)
EP (1) EP3237018A4 (es)
JP (1) JP2018502107A (es)
KR (1) KR20170105529A (es)
CN (1) CN107405413A (es)
AU (1) AU2015371325A1 (es)
BR (1) BR112017013765A2 (es)
CA (1) CA2971583A1 (es)
CL (1) CL2017001701A1 (es)
CO (1) CO2017007383A2 (es)
EA (1) EA201791471A1 (es)
EC (1) ECSP17040003A (es)
IL (1) IL253023A0 (es)
MA (1) MA41271A (es)
MX (1) MX2017008462A (es)
SG (1) SG11201705179TA (es)
WO (1) WO2016105516A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107406851A (zh) 2014-10-17 2017-11-28 诺格尔制药有限公司 利用smad7反义寡核苷酸治疗受试者的方法和组合物
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
WO2018111323A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Methods and ingestible devices for the regio-specific release of smad7 inhibitors at the site of gastrointestinal tract disease
EP3554345A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
BR112020020957B1 (pt) * 2018-05-09 2022-05-10 Ionis Pharmaceuticals, Inc Compostos oligoméricos, população e composição farmacêutica dos mesmos e seus usos
CN112400019B (zh) 2018-06-27 2024-05-07 Ionis制药公司 用于减少lrrk2表达的化合物和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399550A1 (en) * 2000-02-23 2001-08-30 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
EP1506002A4 (en) * 2002-05-17 2006-06-07 Protein Design Labs TREATMENT OF CROHN'S DISEASE OR PSORIASIS FROM ANTI-INTERFERON GAMMA ANTIBODIES
ITRM20030149A1 (it) * 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
EP2059234B1 (en) * 2006-09-08 2011-11-02 Ore Pharmaceuticals Inc. Method for reducing or alleviating inflammation in the digestive tract
EP2476416A1 (en) * 2006-11-17 2012-07-18 Shire Development Inc. Method of Treatment for Inflammatory Bowel Disease
US20110150871A1 (en) * 2008-08-18 2011-06-23 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists
MX2011005042A (es) * 2008-11-13 2011-08-17 Giuliani Int Ltd Composiciones antisentido, y metodos para obtener y usar las mismas.
TR201000680A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
CN104040349B (zh) * 2011-09-15 2017-07-04 诺格尔制药有限公司 用于监测对抗smad7疗法的反应性的方法
MA39963A (fr) * 2014-05-09 2017-03-15 Nogra Pharma Ltd Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
CA2964673A1 (en) * 2014-10-17 2016-04-21 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
EP3207135A2 (en) * 2014-10-17 2017-08-23 Celgene Alpine Investment Company II, LLC Isotopologues of smad7 antisense oligonucleotides

Also Published As

Publication number Publication date
EP3237018A1 (en) 2017-11-01
CN107405413A (zh) 2017-11-28
KR20170105529A (ko) 2017-09-19
MA41271A (fr) 2017-10-31
SG11201705179TA (en) 2017-07-28
JP2018502107A (ja) 2018-01-25
WO2016105516A8 (en) 2017-07-06
IL253023A0 (en) 2017-08-31
US20190112608A1 (en) 2019-04-18
EA201791471A1 (ru) 2017-12-29
AU2015371325A1 (en) 2017-07-13
CL2017001701A1 (es) 2018-04-06
ECSP17040003A (es) 2017-10-31
WO2016105516A1 (en) 2016-06-30
EP3237018A4 (en) 2018-07-11
CA2971583A1 (en) 2016-06-30
BR112017013765A2 (pt) 2018-02-27
MX2017008462A (es) 2018-02-26

Similar Documents

Publication Publication Date Title
CO2017007383A2 (es) Métodos para utilizar oligonucleótidos antisentido para smad7
CL2017003006A1 (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
DOP2017000272A (es) Métodos de diagnóstico para tratamiento con linfocitos t
CY1122143T1 (el) Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
EA201791199A1 (ru) Способ лечения болезни альцгеймера
AR101740A1 (es) Terapia de combinación y composiciones
EA201591679A1 (ru) Способ нетоксического лечения абстиненции, вызванной лекарственным средством
BR112017019413A2 (pt) combinação de agente bactericida com um agente alcalinizante lisossomotrópico para o tratamento de uma infecção bacteriana
CY1122746T1 (el) Ιατρικες αγωγες με βαση την αναμορελινη
BR112016020260A8 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
BR112017005313A2 (pt) formação de imagem e terapia para inflamação e infecção direcionadas por hsp90
CY1117438T1 (el) Μεθοδος για την προληψη και την θεραπευτικη αντιμετωπιση της σηψης
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
ES2967965T3 (es) Dosis y administración de anticuerpos anti-C5 para el tratamiento de enteropatía pierde-proteínas en pacientes
Estenkova et al. About the spa and resort-based treatment of the patients with oncological diseases
EA201692163A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
EA201692164A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
UA96252U (uk) Спосіб лікування гострої анальної тріщини
RU2015100340A (ru) Способ оценки фармакоэкономической эффективности лекарственной терапии
TH158984A (th) สารประกอบที่ออกฤทธิ์ในการรักษาและวิธีการใช้ของสารประกอบดังกล่าว
TH168999A (th) สารยับยั้งของ rorc2 ประเภทเฮเทอโรไบไซโคลแอริล และวิธีการใช้ของมัน
EA201600639A1 (ru) Способ очищения толстой кишки